Topical Pharyngeal Anesthesia With Articaine for Gastroscopy

Summary

Topical Pharyngeal anesthesia (TPA) is widely used during upper endoscopy. Articaine is local anaesthetic that have not been previously evaluated in pharyngeal anesthesia for upper endoscopy. The aim of this study was to compare pharyngeal anesthesia with 4% articaine to placebo (Na0,9%) during gastroscopy in terms of benefit on patients' and endoscopists' satisfaction.

Conditions

• Gastroscopy

Interventions

DRUG

articaine

Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures. In dentistry, articaine is used both for infiltration and block injections.

OTHER

9% Sodium Chloride solution for injection

9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.

Sponsors & Collaborators

• Helsinki University Central Hospital

  lead OTHER

Principal Investigators

• Maxim Mazanikov, MD · Helsinki University Central Hospital,Department of Anesthesiology and Intensive Care

• Reino pöyhiä, MD,PhD · Helsinki University Central Hospital,Department of Anesthesiology and Intensive Care

• Marianne Udd, MD,PhD · Helsinki University Central Hospital,Department of Gastrointestinal and General Surgery

• Jorma Halttunen, MD,PhD · Helsinki University Central Hospital,Department of Gastrointestinal and General Surgery

• Leena Kylänpää, MD,PhD · Helsinki University Central Hospital,Department of Gastrointestinal and General Surgery

• Outi Lindström, MD,PhD · Helsinki University Central Hospital,Department of Gastrointestinal and General Surgery

• Martti Färkkilä, MD,Professor · Helsinki University Central Hospital,Department of Medicine, Division of Gastroenterology

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2009-09-30

Primary Completion

2009-12-31

Completion

2009-12-31

Countries

• Finland

Study Locations